Sara Mills

VP, Regulatory Affairs, CMC

Sara brings over 15 years of experience in the cell and gene therapy field, with deep expertise in CMC regulatory strategy and global regulatory affairs. Prior to joining Artiva, Sara was a Senior Principal and Head of the Cell Therapy CMC Department at Dark Horse Consulting (DHC) Group. During her eight-plus-year tenure at DHC, she led a team of subject matter experts supporting over 110 clients and 120 unique products across nine regulatory jurisdictions. In this role, she advised companies from early to late-stage development, driving CMC strategies and regulatory submissions for cell and gene therapies. Sara began her career at UCSF, where she conducted research in epigenetics, and pluripotent stem cells. She has since built a career distinguished by her ability to integrate technical CMC expertise with strategic regulatory insights, enabling cross-functional teams to streamline operations and accelerate development timelines.